PUBLISHER: The Business Research Company | PRODUCT CODE: 1668358
PUBLISHER: The Business Research Company | PRODUCT CODE: 1668358
Levofloxacin is a bactericidal antibiotic belonging to the fluoroquinolone class, and it functions by directly inhibiting bacterial DNA (deoxyribonucleic acid) synthesis. This mechanism of action allows levofloxacin to prevent the growth and replication of bacteria, making it effective in treating various bacterial infections.
The primary types of levofloxacin are 250 mg tablets, 500 mg tablets, and 750 mg tablets. The 250 mg tablets contain levofloxacin at a dosage strength of 250 mg and are employed for the treatment of bacterial infections in the body. These tablets are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. Levofloxacin is commonly used to address infections such as pneumonia, skin infections, kidney infections, bladder infections, among others.
The levofloxacin research report is one of a series of new reports from The Business Research Company that provides levofloxacin market statistics, including the levofloxacin industry's global market size, regional shares, competitors with a levofloxacin market share, detailed levofloxacin market segments, market trends and opportunities, and any further data you may need to thrive in the levofloxacin industry. This levofloxacin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The levofloxacin market size has grown strongly in recent years. It will grow from$1.75 billion in 2024 to $1.85 billion in 2025 at a compound annual growth rate (CAGR) of 5.5%. The growth in the historic period can be attributed to antibiotic demand, increased respiratory tract infections, increased skin and soft tissue infections, emergence of multidrug-resistant strains
The levofloxacin market size is expected to see strong growth in the next few years. It will grow to $2.31 billion in 2029 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to aging population dynamics, increased incidence of respiratory infections, rising cases of urinary tract infections, globalization of antibiotic resistance, expanding surgical procedures. Major trends in the forecast period include adoption in urinary tract infections (UTIs) treatment, exploration of combination therapies, continuous monitoring for safety profile, shift towards outpatient prescriptions, global health preparedness for infectious diseases.
The increasing incidence of bacterial infections is anticipated to drive the growth of the levofloxacin market in the coming years. Bacterial infections are diseases caused by bacteria, which are single-celled microscopic organisms that invade the body. Levofloxacin helps treat various bacterial infections, including strep throat, tuberculosis (TB), and whooping cough (pertussis), by inhibiting DNA topoisomerases and thus blocking DNA synthesis. For instance, in February 2024, a report from the UK Health Security Agency, a government body in the UK, indicated that tuberculosis (TB) cases in England rose by 10.7% in 2023, with 4,850 cases reported compared to 4,380 in 2022. Consequently, the rising number of bacterial infections is fueling the growth of the levofloxacin market.
The growing aging population is expected to contribute significantly to the expansion of the levofloxacin market. An aging population refers to an increasing proportion of individuals aged 60 years and above in a given population. Respiratory infections, particularly pneumonia, are prevalent among the elderly, often requiring prompt and effective antibiotic treatment. For instance, as of September 2023, the World Economic Forum reported that more than 1 in 10 people in Japan are aged 80 or older. This demographic shift towards an aging population is a key factor driving the growth of the levofloxacin market.
A prominent trend in the levofloxacin market is the emergence of advanced and targeted therapies. Major companies in the market are dedicated to innovating new products to enhance efficacy and maintain their market position. For example, in February 2022, Santen Pharmaceutical, a Japan-based pharmaceutical and medical device company, introduced Ducressa-an innovative fixed-dose combination (FDC) of levofloxacin and dexamethasone eye drops. Designed for the prevention and treatment of inflammation and infection associated with cataract surgery in adults, Ducressa represents a breakthrough prophylactic treatment by combining the broad-spectrum antibiotic efficacy of levofloxacin with the anti-inflammatory properties of dexamethasone.
Major companies in the levofloxacin market are engaging in strategic collaborations with prominent manufacturing partners. These strategic partnerships involve cooperative efforts between organizations to achieve specific business objectives. For example, in June 2023, CEOLIA Pharma Company Ltd., a Japan-based specialty pharmaceutical company, launched Comlex Otic Solution 1.5% (levofloxacin hydrate), an antibacterial OTIC solution developed in collaboration with NanoCarrier Co., Ltd., a Japan-based pharmaceutical company specializing in research and development. This novel medication, an antibacterial OTIC solution for treating otitis externa and otitis media, represents an innovative approach in the ears, noses, and throats (ENT) field.
In July 2022, Innoviva Inc., a US-based biopharmaceutical company, completed the acquisition of Entasis Therapeutics Holdings Inc. for $42.4 million. This strategic move aims to enhance Innoviva's portfolio with potentially first-in-class medications for treating multidrug-resistant gram-negative bacteria, including the main asset SUL-DUR. Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company operating in the levofloxacin market, brings expertise in antibacterial and antibiotic medicines to complement Innoviva's strategic objectives.
Major companies operating in the levofloxacin market include Zydus Lifesciences Limited, Dr. Reddy's Laboratories Limited, Lupin Limited, Pax Healthcare, Aden Healthcare, Allenge India Pharmaceuticals Private Limited, Alna Biotech Private Limited, Bestochem Formulations Limited, Divine Savior Healthcare Private Limited, Glenmark Pharmaceuticals Limited, Cipla Limited, Alkem Laboratories Ltd., Sanofi S.A., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Unichem Laboratories, Macleods Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, Jubilant Pharmova Limited , Wockhardt, Hetero Drugs, Sandoz Group AG, Mankind Pharma, Intas Pharmaceuticals Ltd., Strides Pharma Science Ltd., Divis Laboratories Ltd., Ajanta Pharma Ltd., Panacea Biotec Limited
North America was the largest region in the global levofloxacin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the levofloxacin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the levofloxacin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The levofloxacin market consists of sales of levofloxacin-citric acid, levofloxacin hydrochloride, and levofloxacin-d3 sodium salt. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Levofloxacin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on levofloxacin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for levofloxacin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The levofloxacin market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.